Experience

Vibliome Therapeutics, LLC

• United States
• Pharmaceutical Manufacturing
• 1 - 100 Employee

• Co-Founder

  • Jul 2017 - 6 years 6 months

  West Yellowstone, Montana, United States Retired



Spacefill Enterprises LLC

• Founder

  • Dec 2007 - 16 years 1 month

  Tucson, Arizona Area Consulting and detailed medicinal chemistry input to Major and Biotech pharamaceutical companies with a focus on structure-based design. Discovery of novel chemo-types for the inhibition of kinases, MMPs, and PPI as well as PET imaging agents.



Vibliome Therapeutics Inc.

• President and Chief Scientific Officer

  • Sep 2017 - Jul 2021

  Bozeman, MT Development of a kinase inhibitor platform that offers access to unique inhibition profiles and high selectivity.



University of Arizona

• United States
• Higher Education
• 700 & Above Employee

• Research Professor at the BIO5 Institute and Adjunct Research Professor

  • Jan 1980 - Sep 2015

  Graduate Teaching and Research in Medicinal Chemistry



Locus Pharmaceuticals

• Biotechnology
• 1 - 100 Employee

• Head Computational Approaches and Lead Design

  • Jan 2001 - Oct 2003

  Director of Chemistry and later as Head of Computational Approaches and Lead Discovery, I provided scientific direction for both the medicinal chemistry and computational design efforts at Locus. Responsible for the building of the chemistry facilities and hiring of the chemstry group during the first two years of operation.



Aventis Pharmacuticals

• Distinguished Scientist and Head of Chemistry

  • Sep 1977 - Jan 2001

  My last position at Aventis was Distinguished Scientist and acting Head of Chemistry at Selectide, our combinatorial technologies subsidiary in Tucson Arizona. Beginning as an entry level chemist at Richadson-Merrell Pharmaceuticals, my career advanced as the company evolved through mergers to Merrell-Dow, Marion Merrell Dow, Hochst Marion Roussel, to Aventis Pharmaceuticals. My most significant contribution was the design and synthesis of a novel mixed inhibitor of ACE and NEP (AVE-7688 or… Show more My last position at Aventis was Distinguished Scientist and acting Head of Chemistry at Selectide, our combinatorial technologies subsidiary in Tucson Arizona. Beginning as an entry level chemist at Richadson-Merrell Pharmaceuticals, my career advanced as the company evolved through mergers to Merrell-Dow, Marion Merrell Dow, Hochst Marion Roussel, to Aventis Pharmaceuticals. My most significant contribution was the design and synthesis of a novel mixed inhibitor of ACE and NEP (AVE-7688 or Ilepatril) which is currently in final stages of studies at Sanofi-Aventis and is expected to launch in 2010. Show less